Mon-Fri 9:00-18:00 CET+39 095 7211344info@vitasanlabs.com

Family · Pharmaceutical analytical standards

Imiquimod

An immune response modifier of the imidazoquinoline family, applied to the skin as a cream: approved in the United States in 1997 for genital warts, it is also used for actinic keratoses and some superficial basal cell carcinomas. This family brings together the active ingredient, pharmacopoeial impurities, labelled standards and other impurities.

Did you know?It does not directly kill viruses or tumour cells: it activates the TLR7 receptor on immune cells, a target identified only in 2002, five years after approval.

ImiquimodGo to the active ingredient →
ImiquimodActive ingredientImiquimodCat. No. P-I034-001CAS 99011-02-6
Imiquimod-d9Isotopically labelledImiquimod-d9Cat. No. P-I034-008CAS 2712126-48-0

Need a molecule you cannot find?

Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.